To address challenges with error-prone, manual molecular testing workflows, Thermo Fisher Scientific has introduced Diomni Enterprise Software, helping streamline routine diagnostics testing for standardization and faster time-to-results. By connecting workflow steps within one interface, Diomni Enterprise can increase a lab’s ability to dynamically respond to today’s rapidly changing testing environment. The solution can be used by a variety of labs performing routine quantitative polymerase chain reaction (qPCR) diagnostic tests and by developers to increase the speed of innovation for emerging testing solutions.
Molecular diagnostics clinical labs and kit manufacturers often suffer from antiquated systems that can be hard to scale for increased throughput or expanding test menu. Further, manual and inefficient steps may make it difficult to track samples and maintain compliance, which is critical for a molecular diagnostics laboratory. For assay developers, transitions between development stages and a lack of process standardization can slow time-to-market and jeopardize regulatory compliance.
Addressing these challenges, Diomni Enterprise seamlessly connects the individual steps of the workflow in one unified platform to improve productivity of qPCR workflows. Diomni Enterprise empowers labs to operate at their highest potential by automating the interface with existing laboratory information systems (LIS) for enhanced efficiency and traceability.
“During the pandemic, we worked to quickly launch a digital solution that would allow clinical labs to continue operations, taking into account the dramatic changes in the PCR testing landscape,” says Fernando Beils, vice president, general manager of qPCR instruments, Thermo Fisher Scientific. “What followed was the earliest stages of the Diomni solution, delivering a digital platform that supports testing workflows with the flexibility required to accommodate rapidly evolving needs. We have continued to build on this platform and are excited to deliver a more robust and scalable tool for labs and assay developers across testing environments.”
Uniting labs with instruments, assays, and LIS on one system can increase traceability to track samples and reagents throughout the sample journey and allows multiple individual users to access assay templates and results at the same time. Diomni Enterprise supports a variety of different testing workflows including compatibility with research-use only and in vitro diagnostic assays and instruments.
“The new Diomni Software makes it easy to work collaboratively, and we can set up runs, manage past runs and documentation, and interpret fluorescent curves remotely and efficiently without the need to install special software,” says Dr Gustav Quade, laboratory medicine and technical development clinical pathologist at Quade Laboratory in Germany.
The Diomni Enterprise software will be available for live demonstrations in Thermo Fisher Scientific’s booth #2118 at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Expo from July 23-27, 2023 in Anaheim, Calif.